In particular, LIF is considered a potential therapeutic target for multiple sclerosis: Th17 cells are involved in the disease pathogenesis and LIF, through the SOCS3–STAT3(suppressor of cytokine signaling 3—signal transducer and activator of transcription 3) pathway, can inhibit STAT3 phosphorylation and, lastly, Th17 cell differentiation [51]. Here, STAT3 is linked to multiple sclerosis.